Most companies below $200M in market value have no research coverage at all. The sell side cannot pay for it, so the company either lives without it or arranges it. This is how to arrange it without embarrassing yourself in front of your board, your counsel, or your investors.
There are three routes to coverage: a bank initiates on its own, an independent analyst finds you, or you commission it. Only the third is on your calendar. Before you commission anything, get your filings current, write the thesis in one paragraph, and decide who will speak to the analyst. Then evaluate the vendor on four things: whether the research is built from filings, whether it names risks, whether the compensation is disclosed on the page itself, and whether the page stays up. A price target, a guaranteed conclusion, or a report that disappears in 90 days is a promotion, not coverage.
Sell-side initiation is what most executives picture: a bank publishes a rating and a target, and the stock appears on institutional screens. It is funded by trading commissions and banking fees, and a company at $60M in market value generates almost none of either. It happens for micro-caps when a bank has just underwritten an offering, and it usually ends when the banking relationship does.
Independent coverage is the second kind: a newsletter, a research boutique, a well-followed analyst who decides your company is interesting. It is valuable precisely because it is unpaid, and it is unpredictable for the same reason. You can make your company easier to find and easier to understand. You cannot schedule it.
Sponsored coverage is the third: the company engages an independent research publisher to produce and distribute analysis, and the publisher discloses the compensation under Section 17(b) of the Securities Act of 1933. It is lawful, it is common, and it is the only one of the three that arrives on a date you chose. Everything below is about doing it properly.
A credible research publisher will screen you before it takes your money, and a good one will decline companies that fail the screen. Get ahead of that. Three things matter.
Current filings. Research is built from the public record. If the 10-K is late, the 10-Q is missing, or the company is dark on OTC Markets, there is nothing to build from and any publisher who proceeds anyway is not writing research. Fix the filings first.
A thesis in one paragraph. Why is the company worth examining now, and what would have to happen for that view to be wrong? If the CFO cannot write that paragraph, the analyst will write it for you, and it may not be the one you wanted. The risk half of the paragraph is the part that makes the whole thing believable.
A named point of contact. Decide who speaks to the analyst, whether that is the CEO, the CFO, or an outside IR firm, and what they will and will not discuss. Good research notes the level of management access it received. Filings-only coverage is legitimate; pretending access existed when it did not is not.
Ask four questions and listen for the shape of the answers.
What is every figure sourced to? The right answer is a filing, a press release, or a named third-party data provider. The wrong answer is any version of "our proprietary model."
Will the report name risks? If the vendor promises a favorable conclusion, stop the call. Research that cannot say anything negative is advertising, and readers know it within two paragraphs.
Where does the disclosure appear? Section 17(b) requires that the compensation, its source, and its amount be disclosed on the material itself, not on a separate legal page. Ask to see a published example.
What happens to the page after the campaign? Promotion rotates; research stays. A dossier that is still indexed two years later keeps working every time an investor searches the ticker. A report that vanishes when the invoice is paid was never about investors.
The report should read like something a portfolio manager could forward without apologizing. That means a stated thesis, the figures that support it with sources, the capital structure including dilution and convertible exposure, the risks in plain language, and the conditions under which the thesis fails. It means no price target and no buy or sell language, because a paid publisher issuing a target is exactly what regulators look for.
Distribution should be described concretely: to whom, how many, and when. A network of investors who opted in to receive research is different from a paid email blast, and the difference shows up in how the stock trades on publication day. Ask how many people receive the notice and the publication, and how they came to be on the list.
A screen takes a day or two. Production of a 2,000-word dossier from filings takes about a week if the company is responsive, and the best publishers commit to a publication window once the company approves the draft for factual accuracy, not for tone. Distribution is an event with a date. After that the page is permanent, and standing coverage, where the dossier is refreshed after each 10-Q and 10-K, is the option that keeps the record current without a new engagement each quarter.
Watchlist Wire writes a 2,000-word fundamental dossier on each company it covers, every figure cited to a filing, with the compensation disclosed on the page. Companies are screened against five published criteria and some are declined. Each dossier is distributed twice, a notice ahead of publication and the dossier itself to 100,000+ investors, then stays published and indexed. The engagement structure is on the Institutional Partnership page; rates are confirmed on the assessment call.
Yes. Issuer-paid research is lawful in the United States when the publisher discloses the compensation, its source, and its amount on the material itself, as required by Section 17(b) of the Securities Act of 1933. The enforcement record is about undisclosed payments and misleading claims, not about disclosed research.
Research is built from the public record, names risks, makes no price predictions, and discloses who paid for it. Promotion asserts a conclusion, hides or buries the payment, and rotates out when the campaign ends. The presence of a price target or guaranteed positive tone is the fastest tell.
After a company passes the screen and provides access, a filings-based dossier typically takes about a week to produce. Watchlist Wire publishes within 48 hours of the company approving the draft for factual accuracy, then distributes it to its network.
No publisher can promise that, and any that does should be avoided. What documented coverage does is make the company discoverable and understandable: when an investor searches the ticker, there is a permanent analysis to find instead of only filings and press releases. Trading follows attention over time, not on a schedule.
A screened, documented dossier with the compensation disclosed on the page, distributed twice to 100,000+ investors, and permanent.
Institutional Partnership See a published dossier